# PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

> **NCT03193333** · PHASE3 · TERMINATED · sponsor: **Laboratorios Sophia S.A de C.V.** · enrollment: 51 (actual)

## Conditions studied

- Primary Open-angle Glaucoma

## Interventions

- **DRUG:** PRO-122
- **DRUG:** Timolol eye drops
- **DRUG:** Dorzolamide-Timolol Ophthalmic
- **DRUG:** Brimonidine Ophthalmic Solution
- **OTHER:** Placebo1
- **OTHER:** Placebo 2
- **DRUG:** Krytantek

## Key facts

- **NCT ID:** NCT03193333
- **Lead sponsor:** Laboratorios Sophia S.A de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-06
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** Sponsor's prerogative since initial purpose for study shifted according to business strategy.
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193333, "PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03193333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*